https://pubs.acs.org/doi/10.1021/acs.orglett.9b02099
https://www.ncbi.nlm.nih.gov/pubmed/31259557?dopt=Abstract
Enabling Synthesis of ABBV-2222, A CFTR Corrector for the Treatment of Cystic Fibrosis.
Org Lett. 2019 Jul 01;:
Authors: Greszler SN, Shelat B, Voight EA
Abstract
An enabling preclinical synthetic route to cystic fibrosis candidate ABBV-2222 is described. Two stereoselective steps provide access to an aminochroman intermediate with excellent control, and a late-stage demethylation/difluoromethylation sequence provides efficient access to the target molecule.
PMID: 31259557 [PubMed – as supplied by publisher]
PubMed:31259557
